ARIX BIOSCIENCE PLC
Arix Bioscience PLC (ARIX)
Notice of 2021 Annual General Meeting
18-May-2021 / 07:00 GMT/BST
Dissemination of a Regulatory Announcement, transmitted by EQS Group.
The issuer is solely responsible for the content of this announcement.
=----------------------------------------------------------------------------------------------------------------------
Arix Bioscience plc
Notice of 2021 Annual General Meeting
LONDON, 18 May 2021: Arix Bioscience plc, ("Arix" or "the Company") (LSE: ARIX), a global venture capital company
focused on investing in and building breakthrough biotech companies, today announces that its Annual General Meeting
("AGM") will be held at 2:00pm BST on Monday 14 June 2021 at the offices of Brown Rudnick LLP, 8 Clifford Street,
London W1S 2LQ.
The 2021 Notice of the AGM and the Form of Proxy have been posted to shareholders today and, in compliance with Listing
Rule 9.6.1, these documents have today been submitted to the National Storage Mechanism and will shortly be available
for inspection at https://data.fca.org.uk/#/nsm/nationalstoragemechanism.
A copy of the AGM materials are also available on the Investor Relations section of the Company's website.
Given current UK Government guidance, shareholders should not attend the AGM in person but are urged to submit their
votes by proxy. The Directors regret that attendance by shareholders will not be possible this year, but ensuring the
health and safety of shareholders and employees makes this unavoidable.
Prior to the formal business of the AGM, a presentation will be delivered. Access to the presentation and the AGM will
be available to shareholders via webcast on the Company's investor relations website at https://arixbioscience.com/
investor-relations/events-presentations.
Shareholders wishing to raise questions ahead of submitting their votes at the AGM, may do so by emailing
ir@arixbioscience.com.
The Directors believe that the resolutions to be put to the meeting are in the best interests of the Company and its
shareholders as a whole, and unanimously recommend that that shareholders vote in favour of all proposed resolutions.
[ENDS]
For more information, please contact:
Arix Bioscience plc
Charlotte Parry, Head of Investor Relations
+44 (0)20 7290 1072
ir@arixbioscience.com
Optimum Strategic Communications
Mary Clark, Supriya Mathur, Shabnam Bashir
+44 (0)20 3922 1906
optimum.arix@optimumcomms.com
About Arix Bioscience plc
Arix Bioscience plc is a global venture capital company focused on investing in and building breakthrough biotech
companies around cutting-edge advances in life sciences.
We collaborate with exceptional entrepreneurs and provide the capital, expertise and global networks to help accelerate
their ideas into important new treatments for patients. As a listed company, we are able to bring this exciting growth
phase of our industry to a broader range of investors. www.arixbioscience.com
=----------------------------------------------------------------------------------------------------------------------
ISIN: GB00BD045071
Category Code: NOA
TIDM: ARIX
LEI Code: 213800OVT3AHQCXNIX43
OAM Categories: 3.1. Additional regulated information required to be disclosed under the laws of a Member State
Sequence No.: 105600
EQS News ID: 1197515
End of Announcement EQS News Service
=------------------------------------------------------------------------------------
Image link:
https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=show_t_gif&application_id=1197515&application_name=news(END) Dow Jones Newswires
May 18, 2021 02:00 ET (06:00 GMT)
